Literature DB >> 19171115

Mechanisms of antiphospholipid-induced thrombosis: effects on the protein C system.

Denis Wahl1, Aurélie Membre, Christine Perret-Guillaume, Véronique Regnault, Thomas Lecompte.   

Abstract

An acquired resistance to activated protein C (APC) has been demonstrated in patients with antiphospholipid antibodies (aPL). Recent studies report interactions between beta2 glycoprotein I (beta2GPI) and prothrombin-binding antibodies and the protein C system. Some aPL in patients recognize one or more conformational epitopes shared by beta2GPI and catalytic domains of APC. Both beta2GPI and anti-prothrombin antibodies are associated with APC resistance. Several clinical studies have focused on an association between aPL and APC resistance, determined by classic activated partial thromboplastin time-based tests. It has been shown in most studies that APC resistance was associated with lupus anticoagulants. APC resistance is also associated with thrombosis, especially venous thromboembolism. Several recent studies have reported a novel integrated approach of coagulation using calibrated automated thrombography. This technique allows an approach of APC sensitivity without interference with lupus anticoagulants. Clinical associations between APC resistance and thromboembolic events have been demonstrated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19171115     DOI: 10.1007/s11926-009-0011-7

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  32 in total

1.  Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis.

Authors:  D G Wahl; F Guillemin; E de Maistre; C Perret; T Lecompte; G Thibaut
Journal:  Lupus       Date:  1997       Impact factor: 2.911

2.  Invitation to a debate on the serological criteria that define the antiphospholipid syndrome.

Authors:  M Galli; G Reber; P de Moerloose; P G de Groot
Journal:  J Thromb Haemost       Date:  2007-12-07       Impact factor: 5.824

3.  Antibodies against phospholipids and beta 2-glycoprotein I increase the risk of recurrent venous thromboembolism in patients without systemic lupus erythematosus.

Authors:  D G Wahl; E De Maistre; F Guillemin; V Regnault; C Perret-Guillaume; T Lecompte
Journal:  QJM       Date:  1998-02

4.  Activated protein C resistance phenotype in patients with antiphospholipid antibodies.

Authors:  J Aznar; P Villa; F España; A Estellés; S Grancha; C Falcó
Journal:  J Lab Clin Med       Date:  1997-08

5.  Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.

Authors:  D A Horbach; E van Oort; R C Donders; R H Derksen; P G de Groot
Journal:  Thromb Haemost       Date:  1996-12       Impact factor: 5.249

Review 6.  Thrombin generation assays: accruing clinical relevance.

Authors:  H Coenraad Hemker; Raed Al Dieri; Suzette Béguin
Journal:  Curr Opin Hematol       Date:  2004-05       Impact factor: 3.284

7.  Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants.

Authors:  S Liestøl; P M Sandset; M-C Mowinckel; F Wisløff
Journal:  J Thromb Haemost       Date:  2007-11       Impact factor: 5.824

8.  Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?

Authors:  J D Oosting; R H Derksen; I W Bobbink; T M Hackeng; B N Bouma; P G de Groot
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

9.  Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus.

Authors:  Junzo Nojima; Hirohiko Kuratsune; Etsuji Suehisa; Tomio Kawasaki; Takashi Machii; Teruo Kitani; Yoshinori Iwatani; Yuzuru Kanakura
Journal:  Br J Haematol       Date:  2002-08       Impact factor: 6.998

10.  Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells.

Authors:  M Borrell; N Sala; C de Castellarnau; S Lopez; M Gari; J Fontcuberta
Journal:  Thromb Haemost       Date:  1992-09-07       Impact factor: 5.249

View more
  4 in total

Review 1.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

Review 2.  Diagnosis and management of the antiphospholipid syndrome.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Blood Rev       Date:  2017-07-30       Impact factor: 8.250

Review 3.  Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome.

Authors:  Jason S Knight; Yogendra Kanthi
Journal:  Semin Immunopathol       Date:  2022-02-04       Impact factor: 11.759

4.  Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome.

Authors:  Hirohisa Okuma; Yasuhisa Kitagawa; Takashi Yasuda; Kentaro Tokuoka; Shigeharu Takagi
Journal:  Int J Med Sci       Date:  2009-12-05       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.